SIOX VS BIOC Stock Comparison
Performance
SIOX10/100
10/100
SIOX returned -58.25% in the last 12 months. Based on the other stocks in it's sector, it's performance is below average giving it a grade of 10 of 100.
BIOC10/100
10/100
BIOC returned -98.16% in the last 12 months. Based on SPY's performance of -16.96%, its performance is below average giving it a score of 10 of 100.
Forecast
SIOX82/100
82/100
The 38 analysts offering 12-month price forecasts for SIOX have an average target of 0, with a high estimate of 0 and a low estimate of 0 giving it a grade of 82 of 100.
BIOC
"Forecast" not found for BIOC
Technicals
SIOX86/100
86/100
Based on a multitude of SIOX's technicals indicators, it receives a grade of 85 of 100.
BIOC14/100
14/100
BIOC receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Volatility
SIOX10/100
10/100
SIOX had a -3,007.89% lower max drawdown compared to SPY over the last 12 months giving it a grade of 10 of 100.
BIOC50/100
50/100
BIOC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
Dividend
SIOX10/100
10/100
SIOX does not have a dividend payout ratio.
BIOC
"Dividend" not found for BIOC
Profit
SIOX10/100
10/100
Could not get data for SIOX.
BIOC19/100
19/100
Out of the last 20 quarters, BIOC has had 3 profitable quarters and has increased their profits year over year on 3 of them.
Analyst Price Targets
SIOX
"Analyst Price Targets" not found for SIOX
BIOC75/100
75/100
3 analysts offer 12-month price targets for BIOC. Together, they have an average target of 0, the most optimistic target put BIOC at 0 within 12-months and the most pessimistic has BIOC at 0.
Earnings
SIOX
"Earnings" not found for SIOX
BIOC10/100
10/100
BIOC has missed earnings 9 times in the last 20 quarters.
All score calculations are broken down here to help you make more informed investing decisions
Sio Gene Therapies Inc. Common Stock Summary
Nasdaq / SIOX
Healthcare
Biotechnology
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Biocept, Inc. Summary
Nasdaq / BIOC
Healthcare
Diagnostics & Research
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare SIOX to other companies in the same or a similar industry.